Perosphere
- Company typePrivate
- Founded2011
- HeadquartersDanbury, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Perosphere firmographics
Firmographics- Name
- Perosphere
- Website
- https://perosphere.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Perosphere is headquartered
LocationHeadquarters
- HQ city
- Danbury
- HQ country
- United States
- HQ region
- North America
Markets served
Perosphere business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Perosphere product offering
Product offeringCore offering
Perosphere is a specialty pharmaceutical company developing rescue medications — therapeutics intended for rapid use in acute, time-sensitive medical situations. The company focuses on drug development for niche, high-urgency clinical indications rather than broad primary-care indications.
Differentiator
Problem solved
Functional benefit
Products and services
- Rescue medications (pipeline) Therapeutic pharmaceutical products in development intended for rapid use in acute, time-sensitive medical situations, targeting clinical and institutional buyers in acute-care settings.
Companies that use Perosphere
Customer profileIdeal customer profiles1 record
Perosphere technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Perosphere partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
Perosphere competitors and assessment
Company assessmentDirect peers
- ARS Pharmaceuticals: ARS Pharmaceuticals develops neffy, a needle-free nasal epinephrine rescue medication for severe allergic reactions. It is one of the closest direct peers to a specialty pharma company developing rescue medications, sharing therapeutic category, regulatory pathway, and commercial model.
- Adamis Pharmaceuticals: Adamis Pharmaceuticals was a specialty pharmaceutical company focused on rescue medications including SYMJEPI (epinephrine injection) for emergency allergic reactions. It represents a directly comparable rescue-medicine specialty pharma peer with a similar asset profile.
- kaleo (now part of Assertio Therapeutics): kaleo developed AUVI-Q, an epinephrine auto-injector rescue medication, before being acquired by Assertio. It is a direct rescue-medicine specialty pharma peer, particularly relevant for product format and emergency-use therapeutic positioning.
- Amphastar Pharmaceuticals: Amphastar Pharmaceuticals is a specialty pharmaceutical company with a portfolio that includes injectable rescue and emergency-use products such as epinephrine and naloxone. It is a directly comparable specialty pharma with focus on injectable and emergency medications.
- Xeris Biopharma: Xeris Biopharma develops ready-to-use injectable rescue formulations, including Gvoke (glucagon) for severe hypoglycemia and Recorlev. It is a direct specialty pharma peer focused on novel formulations of established rescue therapies.
Broad incumbents
- Emergent BioSolutions: Emergent BioSolutions is a larger specialty pharmaceutical company whose portfolio includes emergency-use products such as NARCAN (naloxone) and other medical countermeasures. It is a broad incumbent in the rescue/emergency therapeutics space.
- Hikma Pharmaceuticals: Hikma Pharmaceuticals is a multinational specialty and generic pharmaceutical company with injectable rescue medications including epinephrine auto-injectors. It is a broad incumbent competing in the same therapeutic categories.
- Viatris: Viatris (formed via Mylan-Upjohn combination) markets the EpiPen epinephrine auto-injector, the dominant branded rescue medication for anaphylaxis. It is a broad incumbent in the rescue medication category with massive commercial scale.
- Sandoz (Novartis generics): Sandoz is the generics and biosimilars arm of Novartis and markets generic epinephrine auto-injector rescue medications. It is a broad incumbent competing on price and scale in the same rescue medication category.
Emerging players
- Biodel: Biodel is a small specialty pharmaceutical company developing glucagon rescue products for severe hypoglycemia, overlapping with the rescue medication therapeutic focus and the specialty pharma business model.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Perosphere social profiles
Digital presencePerosphere financial estimates
Financial estimateRevenue estimate
Valuation estimate
Perosphere leadership team
Management profileNumber of profiles
Profiles1 record
Perosphere funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Perosphere M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Perosphere
What does Perosphere do?
Perosphere is a specialty pharmaceutical company developing rescue medications — therapeutics intended for rapid use in acute, time-sensitive medical situations. The company focuses on drug development for niche, high-urgency clinical indications rather than broad primary-care indications.
When was Perosphere founded?
Perosphere was founded in 2011. It employs 11 to 50 people.
Where is Perosphere based?
Perosphere is headquartered in Danbury, United States, in the North America region.
Who are Perosphere's main competitors?
Direct peers on record are ARS Pharmaceuticals, Adamis Pharmaceuticals, kaleo (now part of Assertio Therapeutics), Amphastar Pharmaceuticals and Xeris Biopharma. Broad incumbents are Emergent BioSolutions, Hikma Pharmaceuticals, Viatris and Sandoz (Novartis generics). Biodel is listed as an emerging player.
Does Perosphere have an API?
No public API is recorded for Perosphere.